Cargando…

NAFLD: From Mechanisms to Therapeutic Approaches

Detalles Bibliográficos
Autores principales:	Gariani, Karim, Jornayvaz, François R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313291/ https://www.ncbi.nlm.nih.gov/pubmed/35885052 http://dx.doi.org/10.3390/biomedicines10071747

Ejemplares similares

Pathophysiology of NASH in endocrine diseases
por: Gariani, Karim, et al.
Publicado: (2021)

NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook
por: Nascè, Alberto, et al.
Publicado: (2022)

Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD
por: Mavromati, Maria, et al.
Publicado: (2021)

Extremely high-dose insulin requirement in a diabetic patient with COVID-19: a case report
por: Jornayvaz, François R., et al.
Publicado: (2020)

Systematic Review and Meta-Analysis of the Usefulness of Epicardial Fat Thickness as a Non-Invasive Marker of the Presence and Severity of Nonalcoholic Fatty Liver Disease
por: Orci, Lorenzo A., et al.
Publicado: (2022)

Effectiveness of Therapeutic Patient Education Interventions in Obesity and Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Correia, Jorge C., et al.
Publicado: (2022)

Increased FGF21 plasma levels in humans with sepsis and SIRS
por: Gariani, Karim, et al.
Publicado: (2013)

Salivary cortisol is not associated with incident insulin resistance or type 2 diabetes mellitus
por: Gariani, Karim, et al.
Publicado: (2019)

Molecular Mechanisms of NAFLD in Metabolic Syndrome
por: Martins, Maria João, et al.
Publicado: (2015)

Staging NAFLD: Diagnostic and Therapeutic Value of TAM Signaling
por: Cubero, Francisco Javier
Publicado: (2019)

Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesity
por: Asrih, Mohamed, et al.
Publicado: (2022)

Is the Mediterranean Diet the Best Approach to NAFLD Treatment Today?
por: Angelico, Francesco, et al.
Publicado: (2021)

Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days
por: Truong-Thanh,, et al.
Publicado: (2022)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Recent Developments in NAFLD
por: Mantovani, Alessandro, et al.
Publicado: (2022)

Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives
por: Fotis, Dimitrios, et al.
Publicado: (2022)

NAFLD/MAFLD: New Evidence
por: Mantovani, Alessandro, et al.
Publicado: (2023)

Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
por: Vitulo, Manuela, et al.
Publicado: (2023)

Oxidative Stress and Inflammation: From Mechanisms to Therapeutic Approaches
por: Gambini, Juan, et al.
Publicado: (2022)

NAFLD: Is There Anything New under the Sun?
por: Lonardo, Amedeo, et al.
Publicado: (2017)

NAFLD - A rising metabolic disease
por: Zeigerer, Anja
Publicado: (2021)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

Lean NAFLD: A not so benign condition?
por: VanWagner, Lisa B., et al.
Publicado: (2018)

Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer
por: Nakayama, Naomi
Publicado: (2022)

Risk Factors for Colorectal Adenoma – Acknowledging the Burden of NAFLD
por: Duvnjak, Marko, et al.
Publicado: (2019)

The heated debate over NAFLD renaming: An ongoing saga
por: Yilmaz, Yusuf
Publicado: (2023)

Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions
por: Hrncir, Tomas, et al.
Publicado: (2021)

Preventative and Therapeutic Effects of Astaxanthin on NAFLD
por: Sayuti, Nor Hafiza, et al.
Publicado: (2023)

Parenteral Nutrition Associated Hepatic Steatosis and NAFLD Intersect at AMPK
por: Guthrie, Gregory
Publicado: (2022)

NAFLD as a risk factor for HCC: new rules of engagement?
por: Masuzaki, Ryota, et al.
Publicado: (2016)

Can cysteinyl cathepsin activity control diet-induced NAFLD?
por: Yu, Chenglin, et al.
Publicado: (2020)

Crossing the Rubicon: Adipose Tissue Autophagy Breaks Out NAFLD
por: Kim, Jieun, et al.
Publicado: (2021)

NAFLD: Mechanisms, Treatments, and Biomarkers
por: Nassir, Fatiha
Publicado: (2022)

The Common Mechanisms of Sarcopenia and NAFLD
por: Zhai, Yu, et al.
Publicado: (2017)

Thioredoxin/Glutaredoxin Systems and Gut Microbiota in NAFLD: Interplay, Mechanism, and Therapeutical Potential
por: Zhu, Minghui, et al.
Publicado: (2023)

Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

Interleukin-18 in metabolism: From mice physiology to human diseases
por: Somm, Emmanuel, et al.
Publicado: (2022)

Interplay between ROS and Autophagy in Cancer and Aging: From Molecular Mechanisms to Novel Therapeutic Approaches
por: Cordani, Marco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1db93hqdvkarif2s8cl7m9orgd